HomeYPSN • SWX
add
Ypsomed Holding AG
Previous close
CHF 344.50
Day range
CHF 333.50 - CHF 345.50
Year range
CHF 291.50 - CHF 441.50
Market cap
4.56B CHF
Avg Volume
14.39K
P/E ratio
23.50
Dividend yield
0.66%
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
| (CHF) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 181.34M | 11.94% |
Operating expense | -8.52M | -120.75% |
Net income | 69.55M | 326.67% |
Net profit margin | 38.35 | 281.21% |
Earnings per share | — | — |
EBITDA | 102.22M | 132.33% |
Effective tax rate | 5.55% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 36.30M | -30.61% |
Total assets | 1.21B | 2.35% |
Total liabilities | 401.49M | -28.19% |
Total equity | 807.19M | — |
Shares outstanding | 13.65M | — |
Price to book | 5.82 | — |
Return on assets | 17.29% | — |
Return on capital | 25.58% | — |
Cash Flow
Net change in cash
| (CHF) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 69.55M | 326.67% |
Cash from operations | 65.19M | 94.90% |
Cash from investing | 78.74M | 222.01% |
Cash from financing | -143.68M | -791.74% |
Net change in cash | -97.00K | 99.11% |
Free cash flow | -3.03M | 91.47% |
About
Ypsomed Holding Inc. is a Swiss multinational medical technology company headquartered in Burgdorf, Switzerland. Founded in 2003, through the break up of Disetronic Group, founded by Willy Michel. Ypsomed specializes in developing and manufacturing injection and infusion systems for self-medication, primarily in the areas of diabetes care and biotechnology.
Products include devices like insulin pens, auto-injectors, and infusion pumps, which help patients manage chronic conditions more easily and independently. In 2025, Ypsomed employs 2,800+ employees and has an annual turnover of 728.9 million Swiss Francs. The company is listed on SIX Swiss Exchange. Wikipedia
CEO
Founded
2003
Website
Employees
2,000
